Q1 EPS Estimates for Sensus Healthcare Cut by HC Wainwright

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Equities research analysts at HC Wainwright reduced their Q1 2025 EPS estimates for Sensus Healthcare in a research note issued to investors on Monday, February 10th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $0.11 per share for the quarter, down from their prior estimate of $0.14. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q3 2025 earnings at $0.10 EPS and Q4 2025 earnings at $0.16 EPS.

A number of other equities analysts have also recently weighed in on SRTS. Lake Street Capital started coverage on shares of Sensus Healthcare in a research report on Friday, January 31st. They set a “buy” rating and a $18.00 price objective for the company. Maxim Group increased their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Stock Up 3.9 %

Shares of Sensus Healthcare stock opened at $6.07 on Tuesday. The business’s fifty day simple moving average is $7.38 and its 200-day simple moving average is $6.89. Sensus Healthcare has a 52 week low of $2.91 and a 52 week high of $9.33. The firm has a market cap of $99.49 million, a PE ratio of 15.18 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

Institutional Trading of Sensus Healthcare

Large investors have recently made changes to their positions in the company. Truvestments Capital LLC purchased a new stake in shares of Sensus Healthcare in the 3rd quarter valued at approximately $32,000. IFP Advisors Inc purchased a new position in Sensus Healthcare in the fourth quarter valued at approximately $95,000. Cubist Systematic Strategies LLC acquired a new stake in Sensus Healthcare during the second quarter worth approximately $156,000. XTX Topco Ltd raised its holdings in Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after purchasing an additional 13,619 shares in the last quarter. Finally, Sigma Planning Corp acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $215,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.